A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-04

Trial Profile

A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-04

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Minocycline (Primary)
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Sponsors Foamix
  • Most Recent Events

    • 04 Jan 2018 According to a Foamix Pharmaceuticals media release, results from Open-Label safety extension part will be presented in a poster forum at the Winter Clinical Dermatology Conference 2018.
    • 04 Jan 2018 Results from Open-Label safety extension part were presented in a Foamix media release.
    • 15 Nov 2017 According to a Foamix Pharmaceuticals media release, last subject visit has been completed, ahead of schedule, in the long-term safety extension study and the top-line results from this safety are expected in by the end of this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top